Reneo Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Reneo Pharmaceuticals aumenten en un 70.9% al año. Se prevé que el BPA aumente en un 87.6% al año.

Información clave

65.4%

Tasa de crecimiento de los beneficios

67.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	25.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	17 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Oct 03

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Apr 25

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Nov 22

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Aug 09

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Apr 22

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

Jan 20

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

Oct 02

Our First Look At Reneo Pharmaceuticals

Aug 15

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:RPHM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-24	N/A	N/A	1
12/31/2024	N/A	-22	N/A	N/A	4
3/31/2024	N/A	-71	-76	-76	N/A
12/31/2023	N/A	-77	-64	-64	N/A
9/30/2023	N/A	-67	-60	-60	N/A
6/30/2023	N/A	-61	-52	-52	N/A
3/31/2023	N/A	-54	-48	-47	N/A
12/31/2022	N/A	-52	-48	-47	N/A
9/30/2022	N/A	-49	-42	-42	N/A
6/30/2022	N/A	-49	-41	-41	N/A
3/31/2022	N/A	-46	-39	-38	N/A
12/31/2021	N/A	-40	-38	-38	N/A
9/30/2021	N/A	-35	-33	-33	N/A
6/30/2021	N/A	-28	-29	-29	N/A
3/31/2021	N/A	-22	-23	-23	N/A
12/31/2020	N/A	-19	-19	-19	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que RPHM siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que RPHM siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que RPHM siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de RPHM crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que RPHM no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de RPHM se prevé que sea elevada dentro de 3 años.

Reneo Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 18% to US$20.98

Price target decreased by 9.1% to US$24.40

Price target increased to US$26.83

Price target decreased to US$24.60

Price target decreased to US$30.00

Recent updates

OnKure, Inc. entered into an agreement to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM)

New major risk - Revenue and earnings growth

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) for $60.8 million.

Price target decreased by 18% to US$20.98

Reneo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) announces an Equity Buyback for 576,443 shares, for $4.4 million.

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Chief Development Officer notifies of intention to sell stock

New minor risk - Profitability

Price target decreased by 9.1% to US$24.40

Reneo Pharmaceuticals, Inc. announced that it has received $5 million in funding from Abingworth LLP

Reneo Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from Abingworth LLP

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Reneo Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target increased to US$26.83

Founder & Executive Chairman exercised options to buy US$165k worth of stock.

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Reneo Pharmaceuticals, Inc. Appoints Roshawn Blunt to Its Board of Directors

Reneo Pharmaceuticals, Inc. Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study

Reneo Pharmaceuticals, Inc. to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Value Index

Price target decreased to US$24.60

Price target decreased to US$30.00

High number of new directors

Dr. Lon Cardon Not Stands for Re-Election as Member of the Board of Reneo Pharmaceuticals, Inc

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Reneo Pharmaceuticals, Inc. Announces Senior Leadership Promotions

Vineet R. Jindal to Resign as Reneo Pharmaceuticals, Inc.'s Chief Financial Officer, Effective March 31, 2022

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

High number of new directors

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

President recently bought US$64k worth of stock

Our First Look At Reneo Pharmaceuticals

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento